Yazar "Aksoy, Nurkan" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Comparison of serum vitamin D levels between patients with deficit and non-deficit schizophrenia(Istanbul Universitesi, 2016) Akyol, Esra Soydaş; Aksoy, Nurkan; Şahin, Başak; Beyazyüz, Murat; Tekin, Ülker; Albayrak, YakupObjective: Vitamin D deficiency has been proposed to play role in a series of psychiatric disorders including schizophrenia, however there have not been any knowledge regarding relationship between vitamin D deficiency and deficit syndrome schizophrenia (DS). In this study, we aimed to evaluate the relationship between vitamin D deficiency and deficit syndrome by comparing serum vitamin D levels of deficit schizophrenia patients and non-deficit schizophrenia (NDS) patients. Methods: Sixty-six patients who had the diagnosis of schizophrenia were included. Twenty-six patients comprised the DS group, while forty patients comprised the NDS group. The severity of illness was assessed with Scale of Assessment of Negative Symptoms (SANS), Scale of Assessment of Positive Symptoms (SAPS), and Brief Psychiatry Rating Scale (BPRS). Vitamin D concentrations of both groups were measured by an electrochemiluminescence method. Results: The groups were similar regarding age and gender (t=1.32; p=0.18 and X2=0.35; p=0.36, respectively). The mean SANS score and BPRS was higher in DS group compared to NDS group (t=- 3.86; p<0.001 and t=-2.13; p=0.03, respectively). The mean score of SAPS was found to be higher in NDS group compared with DS (t=-2.17; p=0.03). No statistically significant difference was observed between groups regarding serum 25(OH)D levels (t=1.36; p=0.17). Conclusion: The findings of the present study may suggest that vitamin D deficiency do not play a role in etiology of DS, although previous reports imply a relation between the vitamin D deficiency and schizophrenia. Further studies are needed to clarify the role of vitamin D in subgroups of schizophrenia. © 2016, Istanbul Universitesi. All rights reserved.Öğe Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker(Cambridge Univ Press, 2017) Akyol, Esra Soydas; Albayrak, Yakup; Aksoy, Nurkan; Sahin, Basak; Beyazyuz, Murat; Kuloglu, Murat; Hashimoto, KenjiObjective: The product of the G72 gene is an activator of d-amino acid oxidase and has been suggested to play a role in the pathogenesis of schizophrenia. Increased G72 protein levels may be associated with disturbed glutamatergic transmission and increased reactive oxygen species. Only one pilot study by Lin et al. has investigated the potential role of serum G72 protein levels as a biomarker for schizophrenia. In this study, we aimed to compare serum G72 protein levels between patients with schizophrenia and healthy controls, and to retest the results of the previous pilot study. Materials and methods: In total, 107 patients with a diagnosis of schizophrenia according to the inclusion and exclusion criteria and 60 age-sex-matched healthy controls were included in the study. The groups were compared regarding serum G72 protein levels. Results: The mean serum G72 protein values were 495.90 +/- 152.03 pg/ml in the schizophrenia group and 346.10 +/- 102.08 pg/ml in the healthy control group. The mean serum G72 protein level was significantly increased in the schizophrenia group compared with the healthy control group (t=-3.89, p<0.001). A receiver operating characteristics analysis was performed to compare the schizophrenia and healthy control groups. It was determined that the cut-off value was 141.51 pg/ml with a sensitivity of 0.991 and a specificity of 0.821. Conclusion: We suggest that serum G72 protein levels may represent a candidate biomarker for schizophrenia and have confirmed the results of the previous preliminary study. Additional studies with larger sample sizes and the inclusion of first episode schizophrenia patients are required to clarify the reliability and validity of serum G72 protein levels as a biomarker for schizophrenia.